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The diagnostic landscape of non-small cell lung cancer (NSCLC) is changing rapidly
with the availability of novel treatments. Despite high-level healthcare in the Netherlands,
not all patients with NSCLC are tested with the currently relevant predictive tumor
markers that are necessary for optimal decision-making for today’s available targeted
or immunotherapy. An expert workshop on the molecular diagnosis of NSCLC involving
pulmonary oncologists, clinical chemists, pathologists, and clinical scientists in molecular
pathology was held in the Netherlands on December 10, 2018. The aims of the workshop
were to facilitate cross-disciplinary discussions regarding standards of practice, and
address recent developments and associated challenges that impact future practice. This
paper presents a summary of the discussions and consensus opinions of the workshop
participants on the initial challenges of harmonization of the detection and clinical use
of predictive markers of NSCLC. A key theme identified was the need for broader
and active participation of all stakeholders involved in molecular diagnostic services
for NSCLC, including healthcare professionals across all disciplines, the hospitals and
clinics involved in service delivery, healthcare insurers, and industry groups involved in
diagnostic and treatment innovations. Such collaboration is essential to integrate different
technologies into molecular diagnostics practice, to increase nationwide patient access
to novel technologies, and to ensure consensus-preferred biomarkers are tested.
Keywords: predictive tumor markers, carcinoma, non-small cell lung, molecular targeted therapy, molecular
pathology, precision medicine
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INTRODUCTION
Worldwide, an estimated 1.2 million–1.4 million deaths occur
annually from non-small cell lung cancer (NSCLC) (1, 2). Most
patients present with locally advanced or metastatic disease,
for which the 1-year survival rate is around 20% (3, 4). In
the era of precision medicine, NSCLC is no longer considered
a single entity, but rather a heterogeneous disease comprising
molecularly defined tumor subgroups that require individualized
treatment (5, 6). The current article summarizes the opinions of
18 Dutch experts assessed during a workshop held on December
10, 2018, regarding the harmonization of approaches for optimal
molecular diagnostics accessible for all patients with advanced-
stage NSCLC.
To meet the need for standardization and harmonization
initiatives for diagnostics and treatment, the expert advisory
panel covered a range of disciplines, and included pulmonary
oncologists, clinical chemists, pathologists, and clinical scientists
in molecular pathology. The objectives of the workshop were
to bring together different stakeholders and facilitate cross-
disciplinary discussions for a consensus on current standards
of practice for NSCLC diagnostics in the Netherlands; address
relevant developments to provide a coherent perspective on
future practice; identify challenges and gaps in the trajectory
toward future practice; and disseminate the workshop findings.
SCIENTIFIC BACKGROUND
The diagnostic landscape of NSCLC is changing rapidly with the
availability of novel treatments. When activating mutations of
the epidermal growth factor receptor (EGFR) gene or anaplastic
lymphoma kinase (ALK) gene rearrangements are present,
tyrosine kinase inhibitor treatment can significantly improve
survival (7, 8). Currently in the Netherlands, 70–75% of stage IV
non-squamous NSCLC patients are tested for EGFR mutations
or ALK rearrangements (9). Additional predictive biomarkers
are emerging, including those involving expression levels of
programmed cell death-ligand 1 (PD-L1) (10) and genetic
aberrations of ROS proto-oncogene 1 (ROS1), B-Raf proto-
oncogene (BRAF), MET proto-oncogene (MET), RET proto-
oncogene (RET), and erb-b2 receptor tyrosine kinase 2 (ERBB2;
encoding HER2) (11, 12) and more recently of neurotrophic
receptor tyrosine kinase 1 (NTRK1), NTRK2, NTRK3, and
neuregulin 1 (NRG1) (13). Given that predictive biomarker
validation and implementation in the clinic struggle to match
scientific advancements and new drug approvals, continuous
harmonization of the panel of biomarkers is needed, and testing
for each patient’s tumor prior to treatment initiation should
be pursued.
Compared with platinum-containing chemotherapy,
immuno-oncology (IO) agents that target tumors expressing
programmed cell death-1 (PD-1) and PD-L1 improved
overall survival in PD-L1-expressing advanced NSCLC (14).
In the Netherlands, pembrolizumab has replaced cytotoxic
chemotherapy as first-line treatment. Pembrolizumab and other
IO agents are partnered with validated, but distinct PD-L1
immunohistochemical (IHC) companion and complementary
diagnostic assays, which, despite similar analytical performance,
may lead to interchangeability issues (15). This has led to
ongoing efforts in PD-L1 testing harmonization to facilitate
laboratory implementation and quality testing (16–18). Yet, just
2 years after the approval of pembrolizumab in patients with
a PD-L1 tumor proportion score of 50% or greater, a phase
3 study of patients with untreated metastatic disease without
EGFR mutations or ALK rearrangements/fusions reported that
adding pembrolizumab to standard chemotherapy also improves
overall survival compared with chemotherapy alone, regardless
of PD-L1 status (19). The pace of these developments is evident
and reveals a tension between validation and implementation
of new biomarkers vs. the clinical utility and drug labels that
necessitate the need for implementation. Other developments
have added to this complexity:
• The IO drug durvalumab received European Medicines
Agency approval for locally advanced, unresectable NSCLC
following definitive chemoradiotherapy in adults whose
tumors express PD-L1 on ≥1% of tumor cells (20).
• Tumor mutational burden as a predictor for IO response as
yet lacks standardization and an understanding of its clinical
utility and value in clinical practice (21).
• Liquid biopsy (a process for detecting molecular signatures
originating from the tumor), including circulating tumor
deoxyribonucleic acid (ctDNA) analysis, may cover gaps
caused by sample quality/quantity issues associated with tissue
biopsy, the longstanding gold standard for cancer diagnosis
(22, 23).
◦ In 2016, the United States Food and Drug Administration
granted approval for the first polymerase chain reaction
(PCR)-based liquid biopsy assay (Cobas EGFR v2), which
can be used as a companion diagnostic for EGFRmutations
associated with NSCLC (24–26).
◦ There has been a shift from single-marker PCR-based
testing for ctDNA to broad next-generation sequencing
(NGS) panels capable of testing large numbers of predictive
markers and different mutation classes in a single test
(26, 27).
◦ Although ctDNA kits have become available for oncology
research, guidelines for and routine clinical implementation
of ctDNA testing continue to lag (22).
◦ Despite a joint review in March 2018 concluding that
there is insufficient evidence of clinical validity and
utility for most ctDNA assays in advanced cancer
(28), more recent data are emerging to support the
incorporation of ctDNA plasma NGS into routine NSCLC
management (29, 30).
These and other advances raise questions regarding the optimal
diagnostic pathway in non-squamous NSCLC cases being
considered for personalized therapy. Given the broad range of
test methodologies relevant for predictive markers and their
application, an understanding and clinical guidance are needed
of the different diagnostic tests for available and emerging
biomarkers. These include tumor mutational burden and PD-
L1, serum tumor markers, and ctDNA detected with digital PCR
(dPCR) approaches orNGS, used either alone or as a complement
to tissue diagnostics.
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METHOD
The discussions of the expert panel were complemented by a
literature search and disseminated for peer review.
CHALLENGES THAT IMPACT FUTURE
PRACTICE
Challenge 1: A Predefined Panel of
Diagnostic Markers Is Required
Following routine diagnosis of non-squamous NSCLC,
preservation of sufficient tissue for predictive IHC and molecular
testing is key (31–34). A predefined panel of markers is needed
that can reliably be tested on relatively small tumor biopsies and
with short turnaround time. There is also a need for testing of
continuously emerging biomarkers. From a local perspective,
uptake in molecular diagnostics is changing. For example,
among 6,600 patients diagnosed with stage IV non-squamous
NSCLC in the Netherlands, testing for EGFR mutations in
tumor tissue increased from 24% of cases in 2013 to 44% in
2015 (9). Of the tested tumors that were found to be negative
for mutations in EGFR and Kirsten rat sarcoma viral oncogene
homolog (KRAS; KRASmutations are considered to be mutually
exclusive with ALK fusions), 50% in 2013 and 77% in 2015
underwent testing for ALK rearrangements/fusions. Gaps in
testing may be related to both scarcity of tissue biopsy material,
especially from stage IV disease, as well as unawareness of
current testing possibilities. Currently, university laboratories
are more likely than non-academic laboratories to use
NGS (9, 35, 36).
The current guidelines in the Netherlands (37) are in
accordance with international guidelines (11, 13, 38, 39) and
recommend that molecular testing for EGFRmutations and ALK
rearrangements/fusions should be performed in patients with
metastatic (non-squamous) NSCLC for whom curative treatment
is no longer available. In addition, the same 2015 guidelines
strongly suggest to consider molecular testing for KRAS, ROS1,
RET, ERBB2, and BRAF (37), comparable with the most recent
international guidelines (13, 39). The consensus of the experts
was that there is sufficient evidence to test not only for EGFR
mutations and ALK rearrangements/fusions, but that all patients
with advanced-stage non-squamous NSCLC should be tested for
PD-L1 protein expression with IHC and for alterations associated
with BRAF, ERBB2, KRAS, MET, NRG1, NTRK1, NTRK2,
NTRK3, RET, and ROS1 (Table 1). This allows for treatment in
routine practice and provides access to ongoing trials and named-
patient/early-access programs. There are further considerations
in reaching this consensus:
• Testing is dependent on disease setting and treatment line, as
well as methodology, since at the moment it is still possible to
use techniques other than NGS and comply with guidelines.
• Certain drugs for targeted and immunotherapy appropriate
for any given patient will not always be available at the initial
location of care provided, and thus patients will need to be
referred (requiring coordination of care between treating and
referral centers).
TABLE 1 | Current and proposed molecular testing for NSCLC in the Netherlands.
Current guidelines Consensus
Recommended ALK*, EGFR ALK*, BRAF, EGFR, ERBB2,
KRAS, MET, NRG1, NTRK1,
NTRK2, NTRK3, PD-L1**,
RET, ROS1
Strongly suggested BRAF, ERBB2, KRAS,
RET, ROS1
*Testing with IHC and mutation analysis, **Testing with IHC.
• There is currently not enough clinical evidence to
recommend routine testing for tumor mutational burden and
microsatellite instability in NSCLC.
Except for PD-L1 and ALK, which require IHC for detection, the
other markers should preferably be determined simultaneously
using DNA and RNA-based NGS (supplemented only when
necessary with in situ hybridization), both to conserve
tissue biopsy material and decrease time-to-decision. As
this technology evolves, molecular profiling will likely shift from
its dominant application in late-stage non-squamous NSCLC
to earlier disease stages where its use may maximize patient
outcomes (40). Findings are awaited of the national, multicenter
Lung Cancer Early Assessment (LEMA) trial in the Netherlands,
which is enrolling 1,300 patients to investigate whether
comprehensive molecular profiling across stage I–IV disease
upon suspicion of NSCLC will improve diagnostic efficiency
and patient benefit from personalized therapy (clinicaltrials.gov:
NCT02894853; available from: https://clinicaltrials.gov/ct2/
show/NCT02894853).
Since new therapies and biomarkers emerge quickly, regular
updates to the panel of required biomarkers are needed,
together with frequent modular updates of the multidisciplinary
guidelines, including any biomarkers that are close to clinical
introduction. Because official guidelines are based on evidence-
based data only, the recommendations will be restricted to
a limited set of predictive markers, comparable with other
international guidelines. Themajor challenge for optimal therapy
is also testing for those predictive markers for which specific
drugs are not yet available in standard practice but are
deemed to become available on short notice because of an
already established beneficial toxicity and efficacy profile. Recent
examples are MET or NTRK targeted therapy, at present only
available through participation in company-sponsored clinical
trials or by off-label or compassionate use. In many countries,
off-label prescription of therapy is likely not reimbursed.
Consequently, the legal and financial issues regarding the
diagnostic testing are often not yet arranged. It is, however,
important that laboratories offer the flexibility to physicians
and their patients to choose between panels based on official
guidelines in their (local) hospital and more expanded panels,
including biomarkers that may enable access to clinical trials or
non-registered drug–biomarker combinations.
The experts recommend the formation of a multidisciplinary
committee, endorsed by national specialist medical societies, to
provide annual guidance on biomarker panel content.
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Challenge 2: ctDNA Analysis Is Coming of
Age, but Requires Standardization for
Disease Profiling
Together with a shift from sequential, single-target molecular
testing to concurrent, massively parallel testing using NGS, the
development of liquid biopsy testing and ctDNA detection,
in particular, offers a dynamic, comprehensive, and minimally
invasive tumor-profiling approach (41). Analysis of ctDNA may
be useful in cases where technical issues prevent tissue analysis or
when patients are unable or unwilling to undergo biopsy (42). As
a primary option, ctDNA may negate the need for tissue biopsy
in patients with positive findings; subsequent tissue biopsy would
maintain its utility in patients with negative findings, among
whom high false-negative rates have been reported (30, 43, 44).
Improved sensitivity of ctDNA testing is desirable, with positive
findings associated with high tumor burden and negative findings
more likely to have a reduced tumor load (45, 46).
Blood sampling for ctDNA testing is more easily performed
than tissue biopsy, with potentially faster results compared with
the longer turnaround times needed for tissue biopsies (30).
Additional advantages of liquid biopsy include the potential
for repeat sampling, and a more accurate representation of
overall disease status than a single-site tissue biopsy (47). Health
economic research is needed to confirm the cost–effectiveness of
ctDNA testing and facilitate its clinical use (48). Finally, ctDNA
analysis may identify markers associated with treatment response
and resistance and, in early NSCLC, offer utility in identifying
patients at high recurrence risk (40, 46). Disadvantages of ctDNA
testing include limited sensitivity, restricted clinical utility, loss
of a direct link between a mutation and a given lesion, and
current technical issues regarding sensitive gene fusion detection
in plasma. Where ctDNA itself is already a valid option for
routine testing of actionable hotspot mutations, the technology
(dPCR and/or NGS) can vary (49), and the use of broader panels
vs. single markers in relation to the different applications in
treatment-decision-making (26) needs to be further investigated.
Further issues include lack of reimbursement, dependency on
knowledge about the beneficial application of liquid biopsy, and
interpretation of results.
Challenge 3: Novel Diagnostic Tools Need
to Be Made Available for All Patients
Access to new diagnostic techniques, such as liquid
biopsy/ctDNA analysis, should be available for all patients.
In practice, there are barriers accessing accurate and timely
molecular diagnoses in oncology for reasons other than
availability [e.g., capability to conduct testing, appropriate
quality management systems (i.e., ISO 15189), geographic reach,
guidelines] (36, 50). For EGFR mutation testing in NSCLC,
external quality assessments have found room for quality
improvements in diagnostic services based on a high level of
diagnostic errors (24, 25, 51).
A regionally coordinated approach may assist in organizing
complex molecular testing in accredited, staffed, and equipped
laboratories (either academic or non-academic). This involves
the development of capacity, logistics, and information sharing
in centers equipped to deliver the latest diagnostic services
normally associated with centralized laboratories. Successful
implementation of a regionalized approach to molecular
diagnostics also requires having an acceptable turnaround time
of maximum 2 weeks. When questions justifying the reasoning,
costs, cost–effectiveness, and reimbursement are adequately
addressed, such an approach is more likely to be adopted.
On current evidence, it is difficult to definitively answer
questions about molecular diagnostics. Limited data support a
regionalized approach for patient care, but do not specifically
shed light on molecular diagnostics. A recent US database
analysis found that in NSCLC, treatment at a high-volume center
was independently associated with improved overall survival
(52). Given just 35% of cases were treated at such centers,
regionalization of NSCLC management may improve patient
outcomes. Although such NSCLC data are not available for the
Netherlands, local data provide support for improved survival
at high-volume centers for the systemic treatment of metastatic
pancreatic cancer, but not for the surgical treatment of colorectal
cancer (53, 54).
An understanding of cost and cost–effectiveness is even more
problematic. Limited data suggest that techniques such as NGS
are helpful in identifying mutations that can improve clinical
decision-making at an affordable level (55). This leads into
the issue of reimbursement, which is currently inadequate and
consequently represents a barrier to the implementation of novel
diagnostic innovations (56). Reimbursement in the Netherlands
is further complicated by the Diagnosis Treatment Combination
system, which restricts the healthcare provider in the choice
of diagnostic tests during negotiations with the insurer. New
diagnostic tests must meet the evidential requirements of
individual hospital boards. Individual laboratories are thus
required to negotiate increased internal funding to cover
higher costs of molecular diagnostics. Normally, this occurs
around historical cost data rather than expected costs of
novel molecular tests. Thus, prospective health economic
data are needed to support novel diagnostics, together with
improved and unbiased reimbursement, greater transparency,
and improved communication and collaboration between
industry and stakeholders (57, 58).
Challenge 4: Harmonization of Diagnostics
Involves Several Different Steps
Despite consensus that molecular testing should be the standard
of care in the management of patients with NSCLC (59), the
biomarker landscape is rapidly changing. Awareness among
centers of actionable drivers and their related biomarker-targeted
treatments is an important first step toward harmonization,
potentially leading to collaboration and broad access to
diagnostic tools offering the greatest utility. This necessitates
a consensus about which diagnostic tools and markers to
adopt as standard care. Current issues that remain unresolved
include the lack of harmonization in preanalytical conditions,
varying performance, lack of comparison between diagnostic
technologies, and the absence of a standardized approach in
applying the different techniques (60).
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Achieving a consensus over the minimal requirements
and performance of any given diagnostic approach requires
multidisciplinary collaboration between treating physicians,
pathologists, clinical chemists, molecular laboratories, and other
stakeholders (61). Healthcare institutions and payers need to be
involved in any conversation. Questions for the former might
seek to understand any requirements for personnel, specialized
equipment, and administrative support. Ultimately, the aim of
harmonization is to ensure a robust and comprehensive final
diagnosis through which to direct treatment and achieve optimal
outcomes. Therefore, the healthcare service provider requires
not only the physical infrastructure, but also the communication
networks to facilitate effective collaboration among healthcare
professionals involved in providing the comprehensive diagnosis
(62). This may require ongoing education to meet the needs of
all stakeholders.
Given the continuous flow of upcoming biomarkers and novel
technologies, a further step toward a validated, harmonized
diagnostic approach is to extend the conversation to the
pharmaceutical and diagnostics industry, which may help
facilitate communication between medical specialists and
healthcare institutions/payers. Harmonization is a long-term
process that is ideally evidence-based yet also innovative,
facilitates close interactions between the laboratory and clinician,
and is a shared responsibility for all stakeholders (63). Industry
involvement could help to establish pilot projects between
healthcare institutions and insurers, and provide financial
support through which to assess proposed diagnostic approaches
for routine use, with a view to better understanding issues such
as indications, tissue requirements, turnaround times, reliability,
pitfalls, and costs (59, 61, 64, 65).
CONCLUSIONS
The overarching challenge in NSCLC management is to
implement the science behind predictive biomarkers into routine
clinical practice where the aim is to translate diagnostic
findings into an optimal, individualized treatment pathway. This
requires collaboration between healthcare professionals involved
in the diagnosis and treatment of NSCLC (medical specialists)
(62), other stakeholders at the point of care (healthcare
institutions), reimbursement (payers), and innovation (industry).
Whereas NSCLC diagnosis has proceeded gradually in the
molecular era, with biomarker testing often varying considerably
between institutions (9, 66), it is important to align diagnostic
approaches with clinical needs and to harmonize between
laboratories. Recently, several projects have been initiated in the
Netherlands to address the discussed issues. These projects aim
at harmonization and evidence-based introduction of state-of-
the-art biomarkers in diagnostic laboratories in the Netherlands.
Examples of such projects are PATH (Predictive Analysis
for Therapy; available from: https://www.netwerk-PATH.nl)
and COIN (ctDNA on the road to implementation in the
Netherlands; available from: www.cfDNA.nl). The coming years
will show the value of such national initiatives in implementing
new biomarkers. For the moment, it is recommended that
molecular testing for metastatic NSCLC analyses is performed on
tumor tissue or cytological material, and that the use of ctDNA
analyses is reserved for those patients who cannot undergo
tumor sampling.
The consensus of the experts was that all patients with
advanced-stage non-squamous NSCLC should be tested for
EGFR mutations and ALK rearrangements/fusions, PD-L1
protein expression with IHC, and alterations associated with
BRAF, ERBB2, KRAS, MET, NRG1, NTRK1, NTRK2, NTRK3,
RET, and ROS1.
Continuous adaptation of guidelines is needed to keep
pace with scientific progress. The present discussion
document identifies the main challenges with developing
and implementing a harmonized approach to molecular
diagnostics in NSCLC treatment. It is challenging to establish
a role for novel technologies, such as ctDNA testing, and to
make these routinely available for all patients. This requires
awareness among stakeholders and necessitates multipartite
collaboration to obtain a comprehensive understanding of a fully
implemented diagnostic network that fulfills the clinical needs for
routine care.
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